Jeremy Abramson, MD on CAR T-Cell Therapy
Kiss 108 FM’s Billy Costa gets a doctor’s perspective of CAR T-cell therapy with Mass General Cancer Center’s clinical director for the Center of Lymphoma, Dr. Jeremy Abramson.
About Jeremy Abramson, MD
Dr. Abramson is Professor of Medicine at Harvard Medical School and Director of the Center for Lymphoma at the Mass General Cancer Center. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School. He completed a residency in Internal Medicine at the Massachusetts General Hospital, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson is board certified in Medical Oncology.
Dr. Abramson's clinical and research interests are in lymphoid malignancies, including all non-Hodgkin lymphomas, Hodgkin lymphoma, and chronic lymphoid leukemias. His research involves the design and conduct of clinical trials of new cancer therapies and immunotherapies in lymphomas. Dr. Abramson is the author of numerous research papers and book chapters on lymphoma, and lectures widely.
Departments, Centers, & Programs:
Clinical Interests:
- Chronic lymphocytic leukemia (CLL)
- Hodgkin's lymphoma (also known as Hodgkin's disease)
- Non-Hodgkin's lymphoma (NHL)
Treats:
- Adult
Locations
Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-724-4000
Fax: 617-726-8330
Medical Education
- MD, Mount Sinai School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Brigham and Women's Hospital
- Fellowship, Dana Farber Cancer Institute
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Medical Oncology, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Abramson designs and conducts clinical trials of novel therapies and immunotherapies including CAR T-cells for the treatment of non-Hodgkin lymphomas, Hodgkin lymphoma (Hodgkin's disease), and chronic lymphocytic leukemia (CLL).
Publications
-
- Abramson JS, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. The Lancet 2024.
- Haydu and Abramson. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Advances 2024.
- Abramson JS, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 2023.
- Abramson JS, et al. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Advances 2022.
- Abramson JS, et al. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. Blood Advances 2023.
- Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet 2020.
- Abramson JS, et al. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma. Am Soc Clin Oncol Educ Book 2020.
- Abramson JS, et al. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood 2019.
- Abramson JS, et al. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art. Am Soc Clin Oncol Educ Book 2019.
- Abramson JS, et al. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.New England Journal of Medicine 2017.